Textbook of clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
| Line 124: | Line 124: | ||
'''Statistical Analysis of Clinical Trials''' | '''Statistical Analysis of Clinical Trials''' | ||
Cleaning a dataset | [[Data cleansing|Cleaning a dataset]] | ||
Summary statistics | [[Summary statistics]] | ||
[[Intention to treat analysis|Intent to treat]] versus [[Modified intention to treat analysis|modified intent to treat]] versus as treated | [[Intention to treat analysis|Intent to treat]] versus [[Modified intention to treat analysis|modified intent to treat]] versus as treated | ||
| Line 143: | Line 143: | ||
Handling [[missing data]] | Handling [[missing data]] | ||
Subgroup and [[Interaction (statistics)|interaction analyses]] | [[Subgroup analysis|Subgroup]] and [[Interaction (statistics)|interaction analyses]] | ||
Net clinical benefit analyses | [[Net clinical benefit|Net clinical benefit analyses]] | ||
Cost effectiveness analyses | [[Cost-effectiveness analysis|Cost effectiveness analyses]] | ||
Quality adjusted life year analyses | [[Quality-adjusted life year|Quality-adjusted life year analyses]] | ||
Interim analyses and [[Futility in clinical research|futility analyses]] | [[Interim analysis|Interim analyses]] and [[Futility in clinical research|futility analyses]] | ||
Reporting results | Reporting results | ||
How to write a manuscript | [[How to write a manuscript]] | ||
[[Meta-analysis]] | [[Meta-analysis]] | ||
Positive publication bias | [[Publication bias|Positive publication bias]] | ||
Revision as of 16:18, 25 October 2019
Ethical Issues
Helsinki agreement
Investigational Review Board (IRB)
HIPAA deidentification and reidentification of patients and patient privacy
Regulatory issues and pathways in clinical trials
The 1572 form and investigator responsibilities
Investigational new drug (IND) application
Investigational new drug or device exemption
Designing Clinical Trials
Randomized controlled trials versus observational studies
Pharmacokinetic (PK) and pharmcodynamic (PD) assessment
Advancing from phase 2 to a phase 3 trial
Parallel versus dose escalation studies
Inclusion and exclusion criteria
Secondary endpoints and exploratory endpoints
Sample size and power calculations
Abbreviations used in clinical trials
Operationalizing Clinical Trials
Principal investigator role
Executive committee role
Steering committee role
Nurse coordinator clinical research associate role
Monitor role
Sponsor role
Randomization service
Central laboratory facility
EKG core laboratory
Angiographic core laboratory
MRI core laboratory
Genetics core laboratory
Biomarker core laboratory
Identification of sites
Recruitment of study participants
Schedule of events
Concomitant medications
Clinical event committee or event adjudication committee
(CEC)
Adverse events, serious adverse events and serious unexpected events
Data safety monitoring board (DSMB)
Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients
Protocol adherence
Storage and handling of the investigational product
Data management and designing an electronic data capture form
Source documents
Study completion and close out
Protocol amendments
Publication committee
Statistical Analysis of Clinical Trials
Intent to treat versus modified intent to treat versus as treated
Student's t tests and analysis of variance (ANOVA)
Chi square analysis and Fisher's exact test
Handling missing data
Subgroup and interaction analyses
Quality-adjusted life year analyses
Interim analyses and futility analyses
Reporting results
Study Tools